Stay updated with breaking news from Abiomed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The acquisition gives J&J access to a device that uses shockwaves to break down calcified plaque in heart vessels, similar to how kidney stones are treated.
The acquisition gives Johnson & Johnson access to a device that uses shockwaves to break down calcified plaque in heart vessels, similar to how kidney stones are treated
Johnson & Johnson to acquire Shockwave Medical for $335.00/share in cash, bolstering its cardiovascular intervention portfolio. The acquisition, expected to close by mid-2024, signifies Johnson & Johnson's strategic focus on innovation and market expansion.
Drug major Johnson & Johnson (JNJ) announced Friday its agreement to acquire Shockwave Medical, Inc. (SWAV) for $335.00 per share in cash. The enterprise value of the deal is around $13.
J&J has been rapidly building its portfolio in both medical technology and drug development to help prepare for the impending loss of exclusivity for Stelara, its top-selling drug for psoriasis, in the US next year.